Jain, Rohit K
Snyders, Travis
Nandgoapal, Lakshminarayanan
Garje, Rohan
Zakharia, Yousef
Gupta, Shilpa
Article History
First Online: 15 December 2018
Change Date: 23 May 2019
Change Type: Correction
Change Details: In the original version of this article, which published in <i>Current Treatment Options in Oncology</i>, Volume 20, Issue 12, December 2018, the surname of the third author was captured incorrectly. The name shown above is correct.
Compliance with Ethical Standards
:
: Rohit Jain declares that he has no conflict of interest.Travis Snyders declares that he has no conflict of interest.Lakshminarayanan Nandagopal declares that he has no conflict of interest.Rohan Garje declares that he has no conflict of interest.Yousef Zakharia has received compensation for participating on advisory boards for Pfizer, Novartis, Roche Diagnostics, Castle Biosciences, Exelixis, Eisai, Johnson & Johnson, and Amgen.Shilpa Gupta has received research funding (paid to her institution) from Bristol-Myers Squibb; has received compensation for service on advisory boards from Exelixis, Janssen, ARMO, AstraZeneca, Merck, and Genentech; and has received compensation for service on speakers’ bureaus from Exelixis, Janssen, AstraZeneca, and Genentech.
: This article does not contain any studies with human or animal subjects performed by any of the authors.